Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

COMPLETED
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Description

Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available.

COMPLETED
A Study of ASN007 in Patients With Advanced Solid Tumors
Description

The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.

COMPLETED
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
Description

This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.